A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

NCT05674526 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer Metastatic
Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: WU-NK-101 - Dose Escalation
DRUG: Cetuximab - Dose Escalation
BIOLOGICAL: WU-NK-101 - Cohort Expansion
BIOLOGICAL: Cetuximab - Cohort Expansion

Sponsor

Wugen, Inc.